Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ENSC - Ensysce Biosciences Inc


IEX Last Trade
0.389
-0.020   -5.167%

Share volume: 891,183
Last Updated: Fri 30 Aug 2024 09:59:50 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.41
-0.02
-4.91%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-10.41%
1 Month
-10.23%
3 Months
-32.48%
6 Months
-56.88%
1 Year
-78.53%
2 Year
-99.59%
Key data
Stock price
$0.39
P/E Ratio 
-0.31
DAY RANGE
N/A - N/A
EPS 
-$2.23
52 WEEK RANGE
$0.36 - $2.06
52 WEEK CHANGE
-$0.78
MARKET CAP 
3.483 M
YIELD 
N/A
SHARES OUTSTANDING 
8.817 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.47
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$15,178,452
AVERAGE 30 VOLUME 
$5,113,625
Company detail
CEO:
Region: US
Website:
Employees: 4
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

ensysce biosciences, san diego, ca, is an integrated drug delivery company for both small and large molecules. to overcome the major problem of non-medical use of opioid products, ensysce is using its prodrug technology to improve abuse deterrent properties. the tap bio-md™ abuse deterrent and mpar™ overdose resistant pain platforms, with worldwide intellectual patent protection, eliminate the ability to abuse opioid products by the non-oral route. this abuse is the fastest growing drug problem in the u.s. and it leads to billions in healthcare costs annually. for additional information about ensysce biosciences please visit www.ensysce.com.

Recent news